Soleus Capital Management L.P. Sells 27,390 Shares of GSK plc (NYSE:GSK)

Soleus Capital Management L.P. reduced its holdings in GSK plc (NYSE:GSK - Free Report) by 73.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,110 shares of the pharmaceutical company's stock after selling 27,390 shares during the quarter. Soleus Capital Management L.P.'s holdings in GSK were worth $342,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. HB Wealth Management LLC purchased a new stake in shares of GSK in the 4th quarter worth about $316,000. Ameritas Advisory Services LLC grew its position in shares of GSK by 19.4% in the 4th quarter. Ameritas Advisory Services LLC now owns 34,955 shares of the pharmaceutical company's stock worth $1,182,000 after buying an additional 5,668 shares during the period. HF Advisory Group LLC grew its position in shares of GSK by 12.8% in the 4th quarter. HF Advisory Group LLC now owns 8,743 shares of the pharmaceutical company's stock worth $296,000 after buying an additional 990 shares during the period. J2 Capital Management Inc purchased a new stake in shares of GSK in the 4th quarter worth about $596,000. Finally, M.E. Allison & CO. Inc. purchased a new stake in shares of GSK in the 4th quarter worth about $314,000. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, BNP Paribas assumed coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $40.58.

GSK Price Performance

GSK traded up $0.12 during trading on Wednesday, reaching $38.52. 2,992,912 shares of the company traded hands, compared to its average volume of 4,835,852. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The company has a market cap of $79.47 billion, a P/E ratio of 24.22, a PEG ratio of 1.12 and a beta of 0.51. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.80. The firm has a fifty day simple moving average of $37.33 and a 200 day simple moving average of $36.00.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. GSK's revenue was up 2.1% on a year-over-year basis. During the same period last year, the company earned $0.43 earnings per share. On average, equities analysts forecast that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a $0.4216 dividend. The ex-dividend date is Friday, May 16th. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a yield of 4.38%. GSK's dividend payout ratio (DPR) is currently 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.